Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-Hodgkin's lymphoma (NHL) cell lines with t(14;18) translocation or elevated BCL2 copy number (BCL2(High)) are sensitive to BCL-2 inhibitors like venetoclax.
• Some BCL2(High) NHL cell lines exhibit resistance to single-agent BCL-2 inhibitors.
• Understanding resistance mechanisms and identifying synergistic drug combinations is crucial for improving NHL treatment.

Purpose of the Study:

• To investigate the role of MCL-1 inhibition in sensitizing resistant BCL2(High) NHL cell lines to navitoclax.
• To determine the key anti-apoptotic targets (BCL-2, MCL-1, BCL-XL) driving drug synergy in NHL.
• To evaluate the predictive value of BCL2 status for venetoclax response and identify potential patient populations for combination therapies.

Main Methods:

• Utilized MCL-1-specific inhibitor (A-1210477) and CDK inhibitor (flavopiridol) in combination with BCL-2 inhibitors (navitoclax, venetoclax) and BCL-XL inhibitor (A-1155463).
• Assessed drug synergy and performed chemical segregation experiments to identify key anti-apoptotic targets.
• Compared drug responses in BCL2(High) and BCL2(Low) NHL cell lines.

Main Results:

• The MCL-1 inhibitor A-1210477 sensitized resistant BCL2(High) NHL cell lines to navitoclax, with synergy driven by combined inhibition of MCL-1 and BCL-2.
• Flavopiridol also downregulated MCL-1 and synergized with venetoclax in BCL2(High) cells.
• In BCL2(Low) NHL cell lines, A-1210477 synergized with navitoclax, driven by BCL-XL inhibition.

Conclusions:

• BCL2 status predicts venetoclax efficacy in NHL, both as a single agent and in combination with MCL-1 inhibitors.
• Combination therapy targeting MCL-1 and BCL-2 offers a strategy for overcoming resistance in BCL2(High) NHL.
• BCL2(Low) NHL patients may benefit from combination therapies involving BCL-XL inhibition.